Metabolic and Mitochondrial Changes in Statin-Induced Myopathy
Metabolic and Mitochondrial Changes in Statin-Induced Myopathy
NCT ID: NCT07511686 Phase: Status: COMPLETED Enrollment: 38 Completion: 2024-10-09
Conditions
Statin Adverse Reaction, Statin-induced Myopathy
Interventions
Blood sampling and laboratory assessment, Muscle biopsy
Summary
The goal of this observational study is to learn whether statin-related muscle symptoms are linked to problems in fat metabolism in muscle cells, specifically involving acylcarnitines, in adults taking or not taking statins. The main questions it aims to answer are:
Do patients with statin-associated muscle symptoms have higher acylcarnitine levels in blood and muscle compared to statin users without symptoms and people not taking statins? Do acylcarnitine levels decrease after stopping or reducing statin treatment in affected patients?
Researchers will compare patients with statin-associated muscle symptoms, statin users without symptoms, and individuals not taking statins to see if differences in acylcarnitine levels and muscle metabolism are associated with muscle symptoms.
Participants will:
Provide blood samples for biochemical tests and acylcarnitine analysis Share information about their health, medications, and lifestyle (Optional) undergo a muscle biopsy to study muscle metabolism Some participants with muscle symptoms will have repeat blood tests and possibly a repeat muscle biopsy after statin dose reduction or discontinuation to track changes over time
Primary Outcome
Acylcarnitine concentrations in blood